GlassScriptPhysician profile
Peter Hung - Ngo Vu
NPI 1730295924
$4,030.11
in general payments reported to CMS, 2019-2025
22 companies · $546 in 2025
The $546 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $390 · 2021: $585 · 2022: $581 · 2023: $507 · 2024: $445 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $679.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $613.05 | 2019-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Glaxosmithkline, LLC. | $479.14 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Gilead Sciences, INC. | $370.00 | 2019-2023 | Vemlidy |
| Lilly USA, LLC | $355.87 | 2023-2024 | Taltz |
| Pfizer INC. | $300.52 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $240.01 | 2022 | |
| Csl Behring | $225.00 | 2022 | |
| Sanofi Pasteur INC. | $169.81 | 2019-2025 | |
| Ucb, INC. | $125.01 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.12 | 2021 | |
| Amarin Pharma, INC. | $110.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $37.21 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $33.47 | 2019 | |
| Cognoa, INC. | $30.60 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $29.62 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $24.95 | 2024 | Gvoke Hypopen |
| Alk-Abello, INC | $21.69 | 2025 | Neffy |
| Cipher Pharmaceuticals US LLC | $20.87 | 2025 | Natroba, Spinosad |
| Sobi, INC | $19.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.47 | 2019 | |
| Mission Pharmacal Company | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.